eft226
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04092673)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Eukaryotic initiation factor 4A-IINHIBITOR
EIF4A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc2c(c(OC)n1)[C@]1(O)[C@H](O)[C@H](CN(C)C)[C@@H](c3ccccc3)[C@]1(c1ccc(C#N)cc1)O2- Mol. weight
- 487.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4303782 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04632381 | Phase 1 | Nov 16, 2020 | Effector Therapeutics, Medpace, Inc. |
| NCT04092673 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2019 | Effector Therapeutics, Medpace, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Effector Therapeutics | For profit | 2 | 2 | 2 | 2019 |
| Medpace, Inc. | For profit | 2 | 0 | 2 | 2019 |
2 organizations
Page 1 / 1